[Research Progress of Acquired Resistance Mediated by MET Amplification  in Advanced Non-small Cell Lung Cancer].

Sisi Pan, Na Wang, Xia Song

Open access · greenAbstract readReview

In one paragraph

Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact, top 82% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Sisi PanThe Second Clinical Medical College of Shanxi Medical University, Taiyuan 030001, China.

Na WangThe Second Clinical Medical College of Shanxi Medical University, Taiyuan 030001, China.

Xia SongThe Second Department of Respiratory, Shanxi Provincial Cancer Hospital, Taiyuan 030013, China.

Shanxi Medical University · CNShanxi Provincial Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal-epithelial transition factor (MET) amplification is an important driver of resistance in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and the combination of MET proto-oncogene (MET) and EGFR-tyrosine kinase inhibitors (TKIs) has shown promise in overcoming this molecularly defined acquired resistance. Emerging data also demonstrate MET amplification as a resistance driver to TKIs-treated anaplastic lymphoma kinase (ALK)-, RET-, and ROS1-fusion NSCLC. Here, we review the literature on recent research progress of MET amplification as a resistance driver to targeted therapy in oncogene-driven NSCLC and summarize the progress of clinical strategies to overcome the resistance mechanism. .

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsDrug Resistance, NeoplasmErbB ReceptorsHumansMutationProtein Kinase InhibitorsProtein-Tyrosine KinasesProto-Oncogene ProteinsProto-Oncogene Proteins c-metErbB ReceptorsProtein Kinase InhibitorsProtein-Tyrosine KinasesProto-Oncogene ProteinsProto-Oncogene Proteins c-metAcquired resistanceLung neoplasmsMET amplificationTargeted therapy

Identifiers

PMID36002199

DOI10.3779/j.issn.1009-3419.2022.102.23

PMCPMC9411950

OpenAlexW4293104804

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.